Therapy Areas: Infectious Diseases
GeoVax Labs expands Leidos collaboration
6 March 2019 -

GeoVax Labs, a biotechnology company developing human vaccines, has expanded its partnership with United States-based Leidos, to develop malaria vaccine candidates, it was reported yesterday.

The work will be supported under an agreement granted to Leidos from the United States Agency for International Development (USAID) Malaria Vaccine Development Program (MVDP). USAID has tasked Leidos with advancing promising vaccine candidates against P. falciparum malaria and selected the GeoVax MVA-VLP platform as part of this development effort.

GeoVax's vaccine technology is based on its live Modified Vaccinia Ankara platform, which generates vaccine antigens, in the form of multimeric proteins or non-infectious VLPs, in the individual being vaccinated.

Login
Username:

Password: